
Special statement:
This article is for internal industry communication only and does not make any recommendations for specific brands or products.
The images presented in this article are only used to describe the facts and are not intended as advertisements for any products.
Minors are prohibited from accessing this article.
Key Takeaways:
- Launched across multiple UK channels: IVG Pro 2 has recently been listed on several UK online retailers. Positioned as a pod-based device, it is compatible with the IVG Pro pod ecosystem.
- Specs and puff count: It adopts a 2ml prefilled pod + 10ml refill container configuration and is rated at approximately 10,000 puffs; it offers 33 flavours and 0/10/20mg nicotine options.
- Experience upgrades: Compared with Pro 6000/Pro 12, the key updates focus on a full-screen real-time battery display and Type-C fast charging (claimed to reach full charge in about 30 minutes), enhancing interaction and charging experience.
- Pricing and compliance update: Online pricing in the UK is around £9.99; as of 30 January 2026, 2Firsts’ search of the MHRA database had not found any published entry labelled “IVG / Pro2.”
2Firsts | 2 February 2026
2Firsts has noted that e-cigarette brand IVG has recently launched a new product across multiple online channels in the UK: IVG Pro 2. The product is positioned as a pod-based vape, upgraded from the IVG Pro, and is compatible with IVG Pro pods. It offers a total of 33 flavours and three nicotine strength options: 0mg, 10mg and 20mg.
0/10/20MG nicotine strengths | 33 flavours
2Firsts has compiled the parameter information for the IVG Pro 2, as shown in the chart below:

Channel information shows that the IVG Pro 2 10K adopts a combined specification of a 2ml prefilled pod + 10ml refill container, and is rated to deliver around 10K puffs. Nicotine strength options include 0/10/20mg, and the number of flavours is 33.

The device is equipped with a built-in 1000mAh integrated battery and supports Type-C fast charging. It uses a mesh coil atomisation structure. In terms of usage positioning, the product is designed for MTL (mouth-to-lung) use and features a full-screen display. Based on product images, the screen uses a dynamic UI design and can show the battery level.
For availability and version information, the page lists multiple body colour options (such as black, gunmetal grey, blue, red, green, purple, light pink, bright pink, etc.). The package contents are 1× device + 1× user manual, and it notes that the charging cable is sold separately.
Full-screen display added; Type-C fast charging included
At InterTabac 2025 (the Dortmund International Tobacco Trade Fair in Germany), 2Firsts had previously observed IVG exhibiting the IVG Pro series. The IVG Pro lineup includes IVG Pro 6000 and IVG Pro 12. As an upgraded version of the IVG Pro, the new IVG Pro 2’s core upgrades are reflected in interaction/display, charging experience and rated puff count.

Compared with IVG Pro 6000:
- The rated puff count of IVG Pro 2 increases from 6,000 puffs to 10,000 puffs.
- In terms of battery and charging, Pro 6000 only states that it has a built-in rechargeable battery and supports Type-C, without disclosing capacity or charging time; Pro 2 10K is clearly labelled as 1000mAh and claims approximately 30 minutes to full charge via Type-C.
- For display configuration, Pro 6000 uses only a small screen to show battery level, while Pro 2 10K is labelled as featuring a full-screen display (real-time battery).
With both positioned at 10K puffs, IVG Pro 2 vs. IVG Pro 12:
- For display configuration, Pro 2 is labelled as having a full-screen display and emphasises real-time battery information, while Pro 12 is labelled only with a battery indicator.
- For charging, Pro 12 is described as supporting Type-C/USB-C charging but does not provide a full-charge time; Pro 2 10K further specifies approximately 30 minutes to full charge.

Listed on UK online channels; priced at around £9.99
Currently, IVG Pro 2 has been listed on multiple UK e-cigarette online retailers such as Vape Sourcing, gosmokefree, and vaping101, with pricing around £9.99.

2Firsts checked the database of the UK Medicines and Healthcare products Regulatory Agency (MHRA) and found that IVG published multiple pod entries on 29 January 2016, with nicotine strength listed as 10MG/ML. However, as of publication, information related to products labelled “Brand Name(s): IVG; Brand Sub Type Name(s): Pro2” had not yet been published on the MHRA database.


As a leading global NGP media and think tank, 2Firsts is dedicated to providing the latest product and technological information and insights to practitioners around the world in various categories such as e-cigarettes, heated tobacco products, and modern oral products. It aims to drive technological changes and innovations in NGP products worldwide, thereby offering tobacco consumers globally with safer products and lifestyles.
With a source of information covering the supply chains in China and global markets, 2Firsts product coverage has become one of the most influential platforms for new product and technology releases globally.
Contact 2Firsts for the following services:
1. Providing leads on new products and technologies;
2. Offering comments on products and technologies;
3. Seeking media coverage for your products;
4. Identifying sales channels for products.
Contact Information: Email: info@2firsts.com
Contact CEO Alan Zhao of 2Firsts on LinkedIn.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com








